Dr. John Cush RheumNow
5 years 6 months ago
Claims data analysis (MarketScan, Medicare, Optum) of 87,653 RA patients starting either TNF inhibitor or tofacitinib shows venous thromboembolism (VTE) is rare (<1 per 100) RA Rx with either. VTE risk was same for Tofa and TNFi (HR of 1.13 [0.77-1.65]) https://t.co/UoMQRp12vo
A two day FDA review by the Drug Safety and Risk Management and Arthritis Advisory Committees has yielded a 19-1 vote against the approval of tanezumab, a nerve growth factor inhibitor, for use in osteoarthritis (OA).
Dr. John Cush RheumNow
5 years 6 months ago
#RNL2021 https://t.co/bZdTYFdEn4
Dr. John Cush RheumNow
5 years 6 months ago
News Feature: Safety of Paternal DMARD or Biologic Use
https://t.co/9jCNJ9rHYF https://t.co/SIRPcPQxyB
Dr. John Cush RheumNow
5 years 6 months ago
Retrospective study of 162 ANCA-Assoc Vasculitis patients (63% GPA, 37% MPA) - risk of serious infx was 7.5 per 100Pt-Yrs & was higher with cyclophosphamide that RTX induction. Risks for SIE:plasmapheresis dialysis & high BVAS in 1st year https://t.co/kAlz9aGQup
k dao KDAO2011
5 years 6 months ago
Dr. Fleischmann vs. Dr. Matsumoto: get rid of MTX vs. get rid of biologic in RA remission. Both argue on sustained remission, risk for anti-drug antibodies, longterm safety. Dr. Buch’s perfect answer… “it depends on patient’s preference, cost.” #RNL2021 https://t.co/FBf2uoDx0B
Dr. John Cush RheumNow
5 years 6 months ago
Why Pain Consults present Not Taking Pain Meds
https://t.co/75YO027Oh6 https://t.co/rir90gM7qv
Dr. John Cush RheumNow
5 years 6 months ago
UTSW Rheum Gr Rounds - Dr Saag
Rules around genetic testing for HLA-B5801 @UTSWIMchief @KenSaag https://t.co/QCpKv0J2s2
Dr. John Cush RheumNow
5 years 6 months ago
UTSW Rheum Gran Rounds - Dr. Ken Saag, Anakinra vs IA steroids @UTSWIMchief @KenSaag https://t.co/M2UCbyuJpb
Dr. John Cush RheumNow
5 years 6 months ago
Dr. Ken Saag giving Rheum Grand Rounds at UT Southwestern. Data showing lower dose colchicine is safer than higher dose in acute gout @UTSWIMchief @KenSaag https://t.co/5KAn9SWlrU
Dr. John Cush RheumNow
5 years 6 months ago
Biologic efficacy in 147 pts w/ eosinophilic granulomatosis with polyangiitis - compares RTX (63), mepolizumab (51) or omalizumab (31). Remission/partial rates were better in RTX (49%/24%) and MEPO (78%, 10%) vs OMA (15%/33%) https://t.co/ZsCFVnasIJ
Dr. John Cush RheumNow
5 years 6 months ago
#RNL2021 https://t.co/8Cs4RZhBpW
Dr. John Cush RheumNow
5 years 6 months ago
Uveitis is uncommonly caused drugs - especially : bisphosphonates, immune checkpoint inhibitors and antiviral drugs. https://t.co/hWO3QFcuMb
In case you missed it, RheumNow Live 2021 delivers what it promises: a good consistent program pack with high energy interactive learning. In the Day 1 learning pods, the audience was given a tour of the new drugs in development for RA. Several noteworthy ones were highlighted by Dr. Roy Fleischmann as listed below:
Dr. John Cush RheumNow
5 years 6 months ago
News Feature: RECIPE Trial - Mycophenolate to Suppress Immunogenicity with Pegloticase in Gout
https://t.co/3TkjwlrSEP https://t.co/GaS8cAJijq
